AAPS Workshop Report: Strategies to Address Therapeutic Protein–Drug Interactions during Clinical Development
Journal Title: The AAPS Journal - Year 2011, Vol 13, Issue 3
Abstract
Therapeutic proteins (TPs) are increasingly combined with small molecules and/or with other TPs. However preclinical tools and in vitro test systems for assessing drug interaction potential of TPs such as monoclonal antibodies, cytokines and cytokine modulators are limited. Published data suggests that clinically relevant TP-drug interactions (TP-DI) are likely from overlap in mechanisms of action, alteration in target and/or drug-disease interaction. Clinical drug interaction studies are not routinely conducted for TPs because of the logistical constraints in study design to address pharmacokinetic (PK)- and pharmacodynamic (PD)-based interactions. Different pharmaceutical companies have developed their respective question- and/or risk-based approaches for TP-DI based on the TP mechanism of action as well as patient population. During the workshop both company strategies and regulatory perspectives were discussed in depth using case studies; knowledge gaps and best practices were subsequently identified and discussed. Understanding the functional role of target, target expression and their downstream consequences were identified as important for assessing the potential for a TP-DI. Therefore, a question-and/or risk-based approach based upon the mechanism of action and patient population was proposed as a reasonable TP-DI strategy. This field continues to evolve as companies generate additional preclinical and clinical data to improve their understanding of possible mechanisms for drug interactions. Regulatory agencies are in the process of updating their recommendations to sponsors regarding the conduct of in vitro and in vivo interaction studies for new drug applications (NDAs) and biologics license applications (BLAs).
Authors and Affiliations
Sandhya Girish, Steven W Martin, Mark C Peterson, Lei K. Zhang, Hong Zhao, Joseph Balthasar, Raymond Evers, Honghui Zhou, Min Zhu, Lewis Klunk, Chao Han, Eva Gil Berglund, Shiew-Mei Huang, Amita Joshi
Keywords
Related Articles
- EP ID EP681334
- DOI 10.1208/s12248-011-9285-6
- Views 62
- Downloads 0
Combined Inhaled Salbutamol and Mannitol Therapy for Mucus Hyper-secretion in Pulmonary Diseases
The online version of this article (doi:10.1208/s12248-014-9560-4) contains supplementary material, which is available to authorized users.
On the Incorrect Statistical Calculations of the Kinetica Software Package in Imbalanced Designs
This regulatory note supports the previous findings that suggest that the software package Kinetica, up to version 5.0.10, provides incorrect results for the 90% confidence intervals for the ratio test/reference where th...
Curcumin Inhibits the AKT/NF-κB Signaling via CpG Demethylation of the Promoter and Restoration of NEP in the N2a Cell Line
Curcumin (CUR), a non-toxic polyphenol from Curcuma longa, has been investigated as a potential therapy with anti-inflammatory and anti-oxidative effects for Alzheimer’s disease (AD), which depicts features of ch...
Chemical Potency and Degradation Products of Medications Stored Over 550 Earth Days at the International Space Station
The online version of this article (doi:10.1208/s12248-015-9834-5) contains supplementary material, which is available to authorized users.
The Coulter Principle for Analysis of Subvisible Particles in Protein Formulations
The Coulter principle can be used for analysis of subvisible particles in protein formulations. The approach has several advantages including: an orthogonal operating principle, high sensitivity, ability to detect very s...